Kairos Pharma reported asset growth of 13.38% for the quarter ended Dec 2025. These growth metrics cover 8 quarters of results from Dec 2023 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Growth MetricsGrowth | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Dec2025 |
|---|---|---|---|---|---|---|---|---|
| Growth Ratios | ||||||||
| Assets Growth (1y) | 497.72% | 13.38% | ||||||
| Assets (QoQ) | 15.27% | 37.60% | -15.93% | |||||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | 3,149.49% | 1,267.74% | 253.07% | |||||
| Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) | -6.06% | -60.46% | 184.28% | -16.10% | ||||
| Cash from Operations Growth (1y)Cash from Ops. Growth (1y) | -2,831.82% | -2,083.33% | -379.17% | |||||
| Cash from Operations (QoQ)Cash from Ops. (QoQ) | -45.45% | -566.67% | -1,102.38% | 10.74% | 60.40% | -12.75% | ||
| EBIT Growth (1y) | -33.45% | -32.78% | -341.11% | -555.86% | ||||
| EBIT (QoQ) | -279.44% | 73.65% | 22.65% | -72.52% | -277.55% | 12.45% | -15.01% | |
| EBT Growth (1y) | -30.79% | -32.42% | -316.50% | -507.69% | ||||
| EBT (QoQ) | -261.59% | 72.25% | 22.77% | -68.80% | -266.08% | 12.72% | -12.68% | |
| EPS (Basic) Growth (1y) | -217.86% | 19.86% | -159.96% | -244.90% | ||||
| EPS (Basic) (QoQ) | -256.67% | 71.60% | 21.67% | -300.65% | 10.08% | 7.88% | -3.92% | |
| EPS (Diluted) Growth (1y) | -217.86% | 19.86% | -159.96% | -244.90% | ||||
| EPS (Diluted) (QoQ) | -256.67% | 71.60% | 21.67% | -300.65% | 10.08% | 7.88% | -3.92% | |
| Free Cash Flow Growth (1y)FCF Growth (1y) | -2,831.82% | -2,083.33% | -379.17% | |||||
| Free Cash Flow (QoQ)FCF (QoQ) | -45.45% | -566.67% | -1,102.38% | 10.74% | 60.40% | -12.75% | ||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | -66.81% | |||||||
| Interest Coverage Ratio (QoQ)Interest Cover (QoQ) | -1,797.21% | 95.06% | -3.14% | -72.52% | ||||
| Net Cash Flow Growth (1y)NCF Growth (1y) | -32,316.67% | 4,522.64% | -2,963.16% | |||||
| Net Cash Flow (QoQ)NCF (QoQ) | -783.33% | 64.15% | 16,921.05% | -160.86% | 220.51% | -124.83% | ||
| Net Income Growth (1y) | -235.58% | 12.34% | -290.71% | -462.06% | ||||
| Net Income (QoQ) | -258.33% | 71.11% | 21.67% | -313.83% | 6.40% | -28.78% | -12.68% | |
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | -235.58% | 12.34% | -290.71% | -462.06% | ||||
| Net Income towards Common Stockholders (QoQ)Net Income (QoQ) | -258.33% | 71.11% | 21.67% | -313.83% | 6.40% | -28.78% | -12.68% | |
| Operating Income Growth (1y)Op. Inc Growth (1y) | -33.45% | -32.78% | -341.11% | -555.86% | ||||
| Operating Income (QoQ)Op. Inc (QoQ) | -279.44% | 73.65% | 22.65% | -72.52% | -277.55% | 12.45% | -15.01% | |
| Profit After Tax Growth (1y)PAT Growth (1y) | -30.79% | -32.42% | -316.50% | -507.69% | ||||
| Profit After Tax (QoQ)PAT (QoQ) | -261.59% | 72.25% | 22.77% | -68.80% | -266.08% | 12.72% | -12.68% | |
| Return on Assets [ROA] (QoQ)ROA (QoQ) | -455.00 | 0.00M | ||||||
| Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) | -164.00 | 0.00M | ||||||
| Return on Equity [ROE] (QoQ)ROE (QoQ) | 0.05M | 261.00 | 0.00M |
Pull Kairos Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KAPA&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KAPA", "statement": "Growth", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KAPA&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();